LEEDS: Tissue Regenix Group (TRX), a regenerative medical devices company, has secured additional coverage with a US Group Purchasing Organization (GPO) for the use of DermaPure, a decellularized allograft dermis, a filing with London Stock Exchange (LSE) said.
The additional coverage will open up access to a further 1,500 hospitals and 32,500 alternative care providers, primarily in the South Eastern region of the US, bolstering the commercial opportunity in Florida, the second largest State with regard to the use of biological tissues such as the DermaPure product.
This expansion builds on Tissue Regenix’s contracts with the two largest GPOs in the US, Premier, Inc. and Vizient, Inc., and with the addition of this new agreement increases potential DermaPure availability into 95% of institutions that purchase via large GPO networks, allowing patients and physicians potential to access the clinical and health economic benefits provided by DermaPure.
Gareth Jones, interim COO of Tissue Regenix Group commented: “GPO approvals play a fundamental role in the Group’s commercialisation strategy for DermaPure, in order to bring this important treatment option to more patients. Another successful approval from a GPO reflects the positive changes we made to our commercial sales strategy where we realigned our efforts to drive adoption directly in the hospital space. This recent approval will provide a more regional focus across the US landscape, furthering our US market penetration efforts.”[the_ad id=”31605”]